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required a discount greater than 61% and 71%, respectively,
from the branded WAC to achieve cost per unit of LDL-C reduc-
tion lower than generic lovastatin. CONCLUSION: To facilitate
effective and efﬁcient management of patients with dyslipidemia,
a tiered formulary could include generic simvastatin or pravas-
tatin as the cost-effective generic statin in the ﬁrst tier (depend-
ing upon level of discount to current WAC) and rosuvastatin as
the cost-effective branded statin in the second tier.
PCV31
COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID
TARGETS WHEN SUBSTITUTING FENOFIBRATE 145 MG FOR
STANDARD FENOFIBRATE THERAPY
Sorensen SV1, Frick KD2, Burge R3, Simko RJ3
1United BioSource Corporation, Bethesda, MD, USA, 2Johns Hopkins
University, Baltimore, MD, USA, 3Abbott Laboratories, Abbott Park, IL,
USA
OBJECTIVES: Clinical evidence suggests that achieving recom-
mended HDL-C levels reduces the likelihood of CHD events and
mortality. The beneﬁts of standard fenoﬁbrate formulation 
on HDL-C and triglyceride levels (TG) are well established;
however, full beneﬁts have typically required administration with
food. Furthermore, evidence suggests that as many as 30% of
people do not comply with food requirements. A new formula-
tion of fenoﬁbrate (fenoﬁbrate 145) that does not require admin-
istration with food has been developed. A cost-effectiveness
model was developed to determine the incremental cost of
meeting additional recommended lipid levels when fenoﬁbrate
145 is substituted for a standard fenoﬁbrate formulation 
that requires food administration in a diabetic population.
METHODS: A simulation model using a managed care per-
spective was designed to predict changes in lipid levels [HDL-C,
LDL-C, TG, and total cholesterol (TC)] and associated drug
costs based on Wholesale Acquisition Costs over the course of
1 year. Lipid targets were based on NCEP-ATP III. A hypothet-
ical cohort of 1000 was modeled for a diabetic population with
abnormal lipid levels based on NHANES data. Lipid changes
were based on the study of fenoﬁbrate by Athyros, et al. 2002.
A reduction in efﬁcacy for each lipid parameter, based on previ-
ously reported work, was applied against patients on standard
fenoﬁbrate therapy (requiring food co-administration).
RESULTS: In a cohort of 1000 patients, substituting fenoﬁbrate
145 for standard fenoﬁbrate therapy resulted in 9.4% more dia-
betic patients reaching TG targets. Seventy-two more patients
(11% increase) on fenoﬁbrate 145 achieved at least 2 targets and
27 more patients (18% increase) achieved at least 3 targets. The
incremental 1 year cost per additional patient reaching TG
targets was $0.78. CONCLUSION: Substituting a non-food
requiring fenoﬁbrate for a standard fenoﬁbrate increases the
number of patients achieving TG and multiple target goals at 1
year at a low cost.
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OBJECTIVES: Previous studies have examined the association
between depression and hypertension. This study aims to
examine whether health status and health care costs differ
between hypertensive patients with and without depression.
METHODS: The study sample was all adult survey respondents
with a self-reported diagnosis of hypertension from the MEPS
(2002–2003). These respondents were also asked about the pres-
ence of conditions related to depression. Health status measures
include SF-12 physical component summary (PCS) and SF-12
mental component summary (MCS) score, and EQ-5D utility
score. Health care utilization was explored in the following cat-
egories: outpatient, inpatient, dental, and pharmacy. The impact
of depression on health status or health care utilization was
explored using multivariate linear regression models with depres-
sion as an independent dummy variable, after controlling for age,
gender, ethnicity, marital status, income, and health insurance.
All analyses are weighted to the US population by the personal
level weights reported in the MEPS data set. RESULTS: Among
a total of 5052 MEPS respondents having hypertension, 1962
reported having (38.84%) depression problems. These two
groups (with and without depression) were comparable in age
and ethnicity. Female hypertensive patients with lower income
level or with Medicare or Medicaid coverage had a higher 
proportion of depression. In regression models, hypertensive
patients with depression had worse health status: SF-12 PCS
score (−5.6, p < 0.0001), SF-12 MCS score (−13.5, p < 0.0001),
and EQ-5D utility score (−0.20, p < 0.0001). Hypertensive
patients with depression had higher utilization of outpatient
($415, p < 0.0001) and pharmacy ($10, p < 0.0001) services, but
both groups had comparable expenditures in inpatient care
($0.09, p < 0.0001) and dental service (−$23, p > 0.05). CON-
CLUSION: In the U.S. population, hypertensive patients with
depression had poorer health status and higher health care
expenditure in outpatient services and prescription drug com-
pared with those without depression. The difference in inpatient
cost between these groups was very small.
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OBJECTIVES: Using recent US national claims data, this study
examined characteristics of managed care patients taking clopi-
dogrel in outpatient settings and analyzed patterns of use.
METHODS: This retrospective study identiﬁed patients with
oral antiplatelet claims in a large, national, managed care claims
database (Pharmetrics) between 1/2003–6/2006 (n = 47,364). All
medical and pharmacy claims were analyzed during this period.
Analysis focused on outpatient use patterns of clopidogrel and
patient characteristics, e.g., demographics, comorbidities, inpa-
tient history, and other cardiovascular medication use. Aspirin
therapy was not available in the prescription claims data.
RESULTS: Clopidogrel was the most widely prescribed
antiplatelet, representing 93% of all prescriptions. Men repre-
sented 65% of the patients taking clopidogrel. The mean age was
56.9 years, with 69% of individuals aged 50 to 65 years. The
most common outpatient diagnoses were essential hypertension
(61%), unspeciﬁed hyperlipidemia (57%), hypercholesterolemia
(44%), and unspeciﬁed chest pain (43%). On average, users of
clopidogrel had 3.41 prescriptions per month in 2006 at a health
plan cost of $376.50/month. Average length of therapy for clopi-
dogrel was 292 days. By patient type, it varied from 283 days
for coronary artery bypass surgery, 336 days for percutaneous
coronary intervention (PCI), and 344 days for stroke. However,
10.4% of PCI patients took clopidogrel for ≤30 days. Patients
reﬁlled their clopidogrel prescriptions for 93% of the daily
regimen needed during therapy. Frequent concomitant cardiac
medications included statins (63.9%), beta-blockers (55.0%),
ACE-inhibitors (48.7%), and diuretics (14.2%). Data show that
40–50% of patients discontinued another concomitant cardiac
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medication upon discontinuing clopidogrel. CONCLUSION:
Clopidogrel was the dominant oral antiplatelet by market share.
These patients also used signiﬁcant pharmacy resources on other
medications. While average duration was largely consistent with
treatment guidelines, variations in individual treatment length
were detected. This ﬁnding suggests inconsistencies in utilization
versus treatment guidelines. Early discontinuation of cardiac
medications in some patients also raises concern.
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OBJECTIVES: Computed tomography angiography (CTA) scan-
ners have advanced patient care by providing cardiologists with
the latest in imaging technology. When deciding to purchase a
CTA scanner, practices must evaluate the economic feasibility of
ownership in terms of both ﬁxed (eg, equipment and facility
costs) and variable costs (ie, consumables costs). The objective
of this study was to provide cardiology practices with a com-
prehensive cost estimate for the cost of consumables incurred for
CTA procedure. METHODS: Practice patterns from a large car-
diology practice were evaluated for all CTA procedures over an
eight-month timeframe. The various consumables utilized for
CTA procedures were captured and classiﬁed into three main cat-
egories: contrast media, drugs, and medical supplies. The average
utilization of each consumable was then evaluated, and the unit
acquisition cost for each consumable was applied to quantify the
average cost of consumables per CTA procedure. RESULTS:
From January 2006 through August 2006, data from 3119 pro-
cedures were evaluated. The average cost of consumables per
procedure incurred by the practice was $83.31. Of this cost,
$32.55 was incurred for contrast medium. Additionally, $9.91
was the average cost per procedure incurred for drugs such as
beta blockers, solu-medrol, diphenhydramine, intravenous
ﬂuids, nitrolingual spray, and antiemetics. The largest compo-
nent of consumables was medical supplies (eg, syringes, needles,
tubing, cannulae, intravenous catheter, dressing/bandages, table
paper, gloves, alcohol pads, etc), which cost the institution an
average of $40.85 per procedure. CONCLUSION: When evalu-
ating the economic feasibility of operating a CTA scanner, car-
diology practices can expect to incur an average of $83.31 per
procedure for consumables.
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OBJECTIVES: Compare impact of nesiritide (a recombinant
natriuretic peptide approved for intravenous treatment of
ADHF) administration within ﬁrst day versus after ﬁrst day on
in-hospital outcomes using an inpatient claims database of 400+
US hospitals and 600,000+ discharges (PREMIER). METHODS:
From 681,690 discharges during 2003 and 2004 in the
PREMIER database, we studied patients with DRG 127 at dis-
charge and ICD 9 codes for primary diagnosis of CHF. First day
nesiritide (D1) was deﬁned as nesiritide + diuretic administration
within 1st day of hospital admission; post-ﬁrst-day administra-
tion (post-D1) was deﬁned as nesiritide administration after ﬁrst
hospital day with diuretic therapy during ﬁrst day. Four out-
comes variables were analyzed: discharge status, hospital and
ICU LOS, and hospitalization cost. Propensity matching and
propensity covariate adjustments were performed in all regres-
sion analyses to remove bias in between-group comparisons.
RESULTS: In all, 8126 patient discharge episodes were identi-
ﬁed as D1 and 793 as post-D1. The D1 group had reduced mor-
tality odds versus post-D1 (0.46, 95% CI: 0.36, 0.59, P <
0.0001). Hospital and ICU LOS were shorter for D1 versus post-
D1 (−4.5 days [95% CI: −4.9, −4.2, P < 0.0001] and −1.7 days
[95% CI: −2, −1.5, P < 0.0001], respectively). Hospital costs
were lower for D1 patients (D1-Post D1): −$6642 (95% CI: 
−$7226, −$6058, P < 0.0001). Adjusted and unadjusted analy-
ses on all four outcomes were consistent and achieved statistical
signiﬁcance. CONCLUSION: This analysis demonstrated that in
two groups of propensity-matched hospitalized patients, those
treated with nesiritide within the ﬁrst day of hospital admission
have better outcomes than those treated with nesiritide later.
These ﬁndings are based on retrospective data sources. A recently
announced prospective randomized, controlled global clinical
trial enrolling 7000+ patients (ASCEND-HF) will provide addi-
tional information.
CARDIOVASCULAR STUDIES—Health Care Use &
Policy Studies
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OBJECTIVES: To study the effects of two sequential changes in
drug cost-sharing policies on adherence to statins and beta-
blockers by seniors in British Columbia. METHODS: For each
drug class, we identiﬁed a baseline cohort of subjects initiating
therapy in the 6 months prior to January 1, 2001, a co-payment
cohort initiating therapy in the 6 months prior to the co-payment
policy introduced January 1, 2002, and a co-insurance cohort
initiating therapy in the 6 months prior the co-insurance policy
introduced May 1, 2003. We calculated the proportion of
patients adherent in each cohort each month, with follow-up for
each cohort beginning at the start of that cohort’s recruitment
period and ending 15 months later. Patients were deﬁned as
adherent during a month if they had a proportion of days
covered (PDC) of 80% or greater, calculated by dividing the
number of days the patient had drug supply available by the
number of cohort membership days the patient contributed in
that calendar month. RESULTS: In the baseline cohort, which
did not experience cost-sharing, 55.8% of statin initiators were
adherent to their statins at month 15. The adherence level in the
co-payment cohort at this time, 9 months after the introduction
of the co-payment policy, was 50.5%. 50.8% of co-insurance
cohort member were adherent. Adherence to beta-blockers was
lower, with 48% of the baseline cohort initiators adherent at
month 15. However, the introduction of the co-payment and co-
insurance policies reduced this adherence level by only 1 per-
centage point. CONCLUSION: The introduction of the
co-payment and co-insurance policies reduced adherence to
statins by 5 percentage points relative to baseline levels, but had
a much smaller effect on beta blocker adherence levels. Policy-
